As health and longevity have grown into mainstream topics, NAD+ (nicotinamide adenine dinucleotide) and its related compounds have long stood as star molecules in the anti-aging field. Recent regulatory updates on NMN have also drawn widespread public attention.
This article breaks down the core differences between members of the NAD+ family, the latest global regulatory developments, and the evolving direction of NAD+ products, to provide a comprehensive, science-backed guide to NAD+ anti-aging supplementation.
Core Differences Across the NAD+ Family
NAD+ (Nicotinamide Adenine Dinucleotide)
NAD+ is a critical coenzyme and signaling molecule in the human body. Its core functions span energy metabolism, DNA damage repair (dependent on PARP enzymes), gene expression regulation (dependent on sirtuin deacetylases), and cellular senescence modulation. It serves as both the energy hub and repair switch that sustains normal cellular function and vital activity.
NAD+ Synthesis Pathways
The human body produces NAD+ mainly through two pathways:
- De novo synthesis pathway: Starting from tryptophan, this pathway proceeds through the kynurenine pathway to generate nicotinic acid mononucleotide (NaMN), which is further converted into NAD+. Active in organs such as the liver, this pathway has relatively low efficiency and is heavily influenced by tryptophan intake and metabolic status.
- Salvage synthesis pathway: Uses precursors such as nicotinamide (NAM), nicotinamide riboside (NR), and β-nicotinamide mononucleotide (NMN) as raw materials.
In this pathway, NAM is catalyzed by nicotinamide phosphoribosyltransferase (NAMPT, the key rate-limiting enzyme of the salvage pathway) to produce NMN, which is then converted into NAD+ by nicotinamide mononucleotide adenylyltransferase (NMNAT).
NR and NMN enter directly into the downstream steps of this pathway, bypassing the NAMPT rate-limiting step. They are the primary precursors relied upon for exogenous NAD+ supplementation.
Absorption and Utilization Characteristics
Endogenous NAD+ is mainly generated from precursors such as NMN and NR. Its levels decline gradually with age (due to decreased NAMPT activity and increased consumption by the CD38 enzyme), unhealthy lifestyle habits (staying up late, excessive alcohol consumption), and disease states.
NAD+ has a large molecular weight and carries an electric charge. After oral administration, it has difficulty crossing the intestinal barrier and is easily broken down by digestive enzymes into small fragments such as nicotinamide, resulting in extremely low oral bioavailability.
NADH (Reduced Form of NAD+)
NADH is the reduced state of NAD+. Its core function is to act as an electron carrier in energy metabolism: it accepts hydrogen atoms and electrons during glycolysis and the tricarboxylic acid cycle, then delivers electrons through the mitochondrial respiratory chain to release energy, while being converted back into NAD+.
NADH Conversion Pathway
NADH is an NAD+ precursor that directly carries energy. Unlike other precursors such as NMN and NR, which require multiple conversion steps and ATP consumption to produce NAD+, NADH itself contributes to ATP synthesis via the electron transport chain as it converts into NAD+. In theory, it has a shorter conversion pathway and higher efficiency.
- Endogenous conversion: During energy metabolism, NAD+ is reduced to NADH after accepting electrons and hydrogen atoms. NADH is then oxidized and dehydrogenated via the respiratory chain to regenerate NAD+, forming the NAD+-NADH cycle that sustains continuous energy metabolism.
- Exogenous supplementation: After oral intake, NADH must first be dehydrogenated intracellularly to convert into NAD+ before participating in NAD+-dependent physiological processes. Essentially, it exerts its effects indirectly by converting into NAD+.
Absorption and Utilization Characteristics
NADH has poor stability and is easily degraded by stomach acid and digestive enzymes such as nucleases, resulting in low oral bioavailability.
Current technologies such as microencapsulated coating and liposomal delivery can improve NADH’s stability and absorption efficiency in the intestinal tract. However, more research is needed to confirm whether it can effectively penetrate cell membranes (including brain cells) after entering the bloodstream. Furthermore, the efficiency of NADH conversion to NAD+ is influenced by cellular energy demand and NADH dehydrogenase activity.
Related Research
Clinical studies show that NADH supplementation can improve fatigue scores in patients with chronic fatigue syndrome, and has a certain auxiliary improvement effect on motor function in patients with Parkinson’s disease.
NR (Nicotinamide Riboside)
NR is the direct precursor of NMN and a vitamin B3 derivative. Its core advantages include a short conversion pathway and low toxicity. It bypasses NAMPT, the rate-limiting enzyme of the NAD+ salvage pathway, and is directly catalyzed intracellularly by nicotinamide riboside kinases (NRK1/2) to generate NMN, which is then rapidly converted into NAD+. It is one of the most widely studied NAD+ precursors in clinical research to date.
Absorption and Utilization Characteristics
NR has a small molecular weight and is electrically neutral, allowing it to rapidly cross the intestinal barrier after oral administration.
After entering the bloodstream, it is mainly taken up by organs such as the liver, kidneys, and brain, and is efficiently converted into NMN intracellularly via NRK (the activity of this enzyme is not significantly inhibited by age or disease), making this conversion pathway relatively efficient.
Additionally, NR supplementation has been confirmed to elevate NAD+ levels in the central nervous system.
Related Research
Multiple trials show that daily oral intake of 100–1000 mg NR in healthy adults significantly raises blood NAD+ levels, with no obvious adverse effects observed from short-term supplementation.
A phase II randomized, double-blind, placebo-controlled clinical trial found that daily NR supplementation in Parkinson’s disease patients not only significantly increased total NAD levels in the brain over time, but also improved cerebral energy metabolism, reduced inflammatory markers, and showed a trend toward improved motor function.
Research also shows that NR has positive effects on patients with chronic obstructive pulmonary disease (COPD). After 6 weeks of supplementation, patients showed elevated blood NAD+ levels and reduced inflammatory factors.
A clinical study on Werner syndrome published in Aging Cell in June 2025 drew widespread attention. Werner syndrome is caused by mutations that impair DNA repair, leading cells to age decades faster than normal.
This newly published double-blind, placebo-controlled study found that daily NR supplementation raised blood NAD+ levels in WS patients by approximately 140%, improved arterial stiffness (an indicator of cardiovascular disease risk), reduced skin ulcer area, and appeared to slow the progression of renal dysfunction.
NMN (β-Nicotinamide Mononucleotide)
NMN is a key direct precursor for NAD+ synthesis. Its core advantage is that it requires only one reaction step (catalyzed by NMNAT) to convert into NAD+, delivering high conversion efficiency. As a naturally occurring substance in the human body with good biocompatibility, it is one of the most intensively researched precursors in the NAD+ supplementation field.
NMN Synthesis Pathways
-
Endogenous synthesis: Endogenous NMN is mainly produced via two pathways: first, nicotinamide (NAM) is catalyzed by the rate-limiting enzyme NAMPT; second, NR is catalyzed by NRK kinase. Declining NAMPT activity with age is one of the key factors leading to NAD+ depletion in the body.
-
Exogenous supplementation and absorption update: A study published in Science Advances in 2025 revealed that the vast majority (~90%) of orally administered NMN is not absorbed directly. Instead, it reaches the colon and is metabolized by gut microbiota into small molecules such as nicotinic acid (NA).
These metabolites then undergo enterohepatic circulation and efficiently synthesize NAD+ in the liver via the Preiss-Handler pathway, before being distributed throughout the body. Experiments in germ-free mice found that intact gut microbiota may be a necessary condition for NMN to elevate endogenous NAD+ levels. This suggests that individual differences in gut health may be a key variable affecting the efficacy of NMN supplementation.
Related Research
The first domestic human clinical trial of NMN for anti-aging conducted in a tertiary hospital was led by Professor Qu Lefeng’s team at the Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), marking a new stage of evidence-based clinical research in this field.
The results showed that compared with the placebo group, subjects taking NMN had significantly elevated levels of aging-related metabolites downstream of NMN in the blood. More importantly, when measured using NAD-capped RNA as a biological age clock, the NMN group showed a significant reduction in biological age.
Beyond objective indicators, the study also recorded improvements in subjects’ self-reported perceptions: 70% of subjects reported reduced daily fatigue, 60% showed lower daily blood pressure readings, and 55% reported improved exercise capacity, reflecting the potential value of NMN in improving overall quality of life.
The New Global Regulatory Landscape: Latest Compliance Updates for NAD+ Family Members
NAD+
Currently, there is no formal regulatory framework for NAD+ globally, placing it in a regulatory gray area.
Major regulatory bodies such as the U.S. FDA, EU EFSA, and Japan’s MHLW have not approved it as a dietary supplement or food ingredient. Most NAD+ products on the market today operate on the edge of non-compliance, with no clear legal status. Consumers should be aware of the risks when purchasing.
NADH
The regulatory status of NADH is largely consistent with NAD+: there is no unified global regulatory standard, and it has not received official approval from major regional regulators.
No special regulatory policies for NADH have been updated in any region to date. It remains in a status of no established identity. Whether products can circulate depends largely on the leniency of local regulation, carrying relatively high compliance risks.
NR
NR is the precursor with the most extensive safety certifications in the NAD+ family. Except for China, most regions have clarified its legal status.
- Europe and the United States: Both EU EFSA and U.S. FDA recognize NR as an eligible dietary supplement ingredient, allowing manufacturers to produce and sell it legally.
- China: NR has not yet been approved as a food or health food ingredient.
- Other regions: Canada, for example, has included NR in its Natural Health Product (NHP) notification system. Manufacturers can sell products normally once they complete notification in accordance with standards.
NMN: Key Regulatory Turning Point in 2025
NMN is the ingredient with the greatest regulatory variation. In 2025, policies in multiple countries and regions underwent critical adjustments, shifting from previous bans or ambiguous status to gradual clarification.
-
United States: From ban to restored legality
In 2022, the U.S. FDA banned NMN from being sold as a dietary supplement under the drug exclusion clause, classifying it as a potential drug. However, in September 2025, the FDA officially revoked this new drug designation and restored NMN’s legal status as a dietary supplement.
The core reason was that the Natural Products Association (NPA) provided evidence proving NMN was already sold as a dietary supplement as early as 2017, prior to relevant new drug research — meeting the predrug marketing principle for dietary supplements. E-commerce platforms in the U.S. have gradually resumed listing NMN products.
-
European Union: Launch of novel food safety assessmentIn July 2025, EU EFSA officially launched a safety assessment of NMN as a novel food. Chinese enterprises have already submitted applications and entered the risk assessment phase. Per EU procedures, the assessment results are expected to be announced in 2026.
-
Japan: Maintains status as a general food ingredientJapan’s Ministry of Health, Labour and Welfare clarified NMN’s status as a general food ingredient as early as 2020. No new restrictions were added in 2025, and enterprises can normally arrange production and sales.
-
China: Accepted as a new food additive varietyIn January 2025, China’s National Health Commission included NMN in the acceptance list for new varieties of food additives, but the final result has not yet been announced.
Three Major Directions of Product Evolution: From Single Supplementation to Precision Anti-Aging
As public understanding of NAD+ family ingredients deepens, related products continue to evolve. From the early focus on single-ingredient purity, the market is gradually moving toward precision and higher efficiency.
1. Dosage: Balancing Efficacy and Safety
Currently, single-serving dosages of NMN products globally range from 250 mg to 1000 mg. Consumer demand for stronger potency has made high-dosage products (500 mg or more per serving) dominant.
However, there is no unified optimal dosage standard to date. Dosage formulation requires a balance between theoretical efficacy and safety. While some studies suggest high doses may raise blood NAD+ levels, large-scale human clinical data supporting a direct link between dosage and efficacy is lacking. The long-term safety of high-dosage products therefore requires further verification.
2. Combination Formulas: From Single Ingredients to Synergistic Effects
Early NAD+ products mostly marketed 99% high purity as their core selling point, but such single-ingredient products are gradually fading from the mainstream. “NMN+” combination formulas have become the norm, with an increasing number adopting the strategy of combining NAD+ precursors with AMPK activators.
The core logic is to achieve synergistic benefits through multi-target action, and to address the limitations that may exist with long-term single NAD+ precursor supplementation.
How does AMPK activation boost NAD+ levels?
- Promotes synthesis: Activated AMPK directly upregulates the gene expression and activity of NAMPT, greatly accelerating the synthesis of NMN from NAM and effectively raising NAD+ levels.
- Reduces consumption: AMPK activation inhibits the activity of CD38, the main NAD+-consuming enzyme that becomes overactivated with age. Inhibiting CD38 reduces NAD+ depletion and helps maintain stable levels.
Activating AMPK also regulates bioenergy metabolism and exerts neuroprotective effects, including promoting mitophagy, reducing cerebral amyloid protein, and increasing BDNF levels.
3. Delivery Technologies: Breaking Absorption Barriers for Real Efficacy
No matter how high-quality the ingredient or how comprehensive the formula, efficacy is greatly compromised if absorption is poor. Pharmaceutical-grade delivery technologies are being widely applied to solve this challenge:
-
Liposomal encapsulation technologyThis technology wraps active ingredients in lipid vesicles with a structure similar to cell membranes, shielding them from degradation in the digestive tract and improving their ability to cross intestinal epithelial cells. For unstable NADH, liposomal encapsulation also prevents oxidative degradation.
-
Small intestine targeted delivery and enteric coating technologyEnteric coating allows active ingredients to pass safely through stomach acid and dissolve only in the neutral intestinal environment. Some designs also use intestinal transporters such as SLC12A8 for targeted release, reducing absorption loss.
-
Other stabilization and absorption-enhancing technologiesSpecial multi-layer coating and acid-control processes are used for NADH to ensure gastric passage stability. Sublingual instant dissolution forms bypass hepatic first-pass metabolism by absorbing directly through the oral mucosa, improving utilization efficiency.
The core goal of all these delivery technologies is to solve the pain point that supplementation does not equal absorption — the efficacy of raw materials depends on delivery technology to be fully realized.